Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide.
Herskowitz
R D
RD
Joslin Diabetes Center, Brigham and Women's Hospital, Boston, Massachusetts.
Jackson
R A
RA
Soeldner
J S
JS
Eisenbarth
G S
GS
D000284:Administration, Oral; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000517:prevention & control*; D004341:Drug Evaluation; D006801:Humans; D007515:Islets of Langerhans / Q000276:immunology; D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D011236:Prediabetic State / Q000188:drug therapy* / Q000276:immunology
D001323:Autoantibodies; D009536:Niacinamide